Cargando…

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation

Aspirin is one of the most widely used medicines. Although aspirin is commonly utilized for the treatment of several medical conditions, its broadest uptake is for the prevention of recurrent ischemic events in patients with atherosclerotic disease. Its mechanism of action of inhibiting platelet act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angiolillo, Dominick J., Prats, Jayne, Deliargyris, Efthymios N., Schneider, David J, Scheiman, James, Kimmelstiel, Carey, Steg, Ph. Gabriel, Alberts, Mark, Rosengart, Todd, Mehran, Roxana, Bhatt, Deepak L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773391/ https://www.ncbi.nlm.nih.gov/pubmed/35060092 http://dx.doi.org/10.1007/s40262-021-01090-2

Ejemplares similares

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2022)

Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
por: Angiolillo, Dominick J., et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023)

When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y(12) Inhibition Induced by Ticagrelor
por: Capodanno, Davide, et al.
Publicado: (2020)

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2016)

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016)

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016)

Formulation, optimization, and pharmacodynamic evaluation of chitosan/phospholipid/β-cyclodextrin microspheres
por: Shan, Lu, et al.
Publicado: (2016)

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
por: Cavender, Matthew A., et al.
Publicado: (2021)

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
por: Stone, Gregg W, et al.
Publicado: (2018)

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
por: De Luca, Leonardo, et al.
Publicado: (2021)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
por: Gutierrez, J. Antonio, et al.
Publicado: (2016)

The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX
por: Yong, Celina M., et al.
Publicado: (2019)

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021)

Assessing Pharmacodynamic Effects of Antiplatelet Agents With Different Mechanisms of Action
por: Schneider, David J., et al.
Publicado: (2021)

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
por: Sweeny, Joseph M., et al.
Publicado: (2017)

Early clinical outcomes as a function of use of newer oral P2Y(12) inhibitors versus clopidogrel in the EUROMAX trial
por: Huber, Kurt, et al.
Publicado: (2017)

Safety and Efficacy of Double Antithrombotic Therapy With Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
por: Capodanno, Davide, et al.
Publicado: (2020)

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
por: Angiolillo, Dominick J., et al.
Publicado: (2021)

Are Patients Getting Their Aspirin's Worth in Ischemic Stroke?
por: Schmaier, Alec A., et al.
Publicado: (2018)

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

Effects of intestinal flora on the pharmacokinetics and pharmacodynamics of aspirin in high-altitude hypoxia
por: Sun, Yuemei, et al.
Publicado: (2020)

A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease
por: Price, Matthew J., et al.
Publicado: (2014)

Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus
por: Sciacqua, Angela, et al.
Publicado: (2021)

Scutellaria baicalensis Extract-phospholipid Complex: Preparation and Initial Pharmacodynamics Research in Rats
por: Chen, Shibin, et al.
Publicado: (2022)

Comparison of Three Aspirin Formulations in Human Volunteers
por: Nordt, Sean Patrick, et al.
Publicado: (2011)

Topical Formulations of Serratiopeptidase: Development and Pharmacodynamic Evaluation
por: Nirale, N. M., et al.
Publicado: (2010)

Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
por: Claessen, Bimmer E., et al.
Publicado: (2020)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022)

Correction to: A Novel Bridging Strategy for Patients Undergoing Emergent Non-Cardiac Surgery with a Recent Coronary Stent
por: Bruck, Cierra, et al.
Publicado: (2018)

A Novel Bridging Strategy for Patients Undergoing Emergent Non-Cardiac Surgery with a Recent Coronary Stent
por: Bruck, Cierra, et al.
Publicado: (2018)

Dissolution and pharmacokinetics of a novel micronized aspirin formulation
por: Voelker, M., et al.
Publicado: (2011)

Influence of Differing Analgesic Formulations of Aspirin on Pharmacokinetic Parameters
por: Kanani, Kunal, et al.
Publicado: (2015)

Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial
por: Ono, Masafumi, et al.
Publicado: (2022)

Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
por: Åstrand, Magnus, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016)

Development of polyherbal antidiabetic formulation encapsulated in the phospholipids vesicle system
por: Gauttam, Vinod Kumar, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9crv0n6q9oaitg8ne8s6qf4rec